As the primary route for elimination of clinafloxacin is renal clearance (CL R ) of unchanged drug, studies were conducted to determine the pharmacokinetic profile of clinafloxacin following administration to young and elderly subjects, subjects with various degrees of renal function, and subjects requiring dialysis. These were open-label studies in which subjects received single oral clinafloxacin doses. Sixteen young subjects (18 to 35 years old) and 16 elderly subjects (>65 years old) were enrolled in a study comparing pharmacokinetic profiles of clinafloxacin in young and elderly subjects. Twenty subjects having various degrees of renal function were enrolled into one of three groups based on degree of renal function as measured by creatinine clearance (CL CR ). Twelve subjects with severe renal impairment requiring dialysis enrolled in a third study. Clinafloxacin was generally well tolerated by all subjects. Clinafloxacin pharmacokinetic profiles in elderly subjects were dependent only on age-related decreases in renal function. Clinafloxacin maximum concentrations in plasma, areas under the concentration-time curves, and terminal elimination half-life values increased with decreasing CL CR values. Total apparent body clearance of clinafloxacin from the plasma after oral administration (CL oral ) and CL R were dependent on CL CR according to the following relationships: CL oral ‫؍‬ 2.3 ⅐ CL CR ؉ 77 and CL R ‫؍‬ 1.74 ⅐ CL CR . Hemodialysis had no significant effect on clinafloxacin clearance. Based on the relationship between CL CR and clinafloxacin CL oral and CL R values, the clinafloxacin dose should be halved in patients having a CL CR of <40 ml/min. Further dose adjustment is not warranted in patients requiring hemodialysis.
Clinafloxacin is an extremely potent member of the fluoroquinolone class of synthetic antimicrobial agents. Compared with available quinolone antibiotics, clinafloxacin usually requires lower drug concentrations for bacterial inhibition and is active against a broader spectrum of organisms. It is effective against many multiple-drug-resistant organisms, including quinolone-resistant strains (5, 6, 7, 10, 12, 16) . Clinafloxacin has been studied primarily in hospitalized adults for the treatment of serious and potentially life-threatening infections, including nosocomial pneumonia, community-acquired pneumonia, febrile neutropenia, complicated intra-abdominal infections, complicated skin and soft tissue infections, endocarditis, and acute gynecologic infections (16) . It became apparent from initial clinical studies that twice-daily 100-to 400-mg doses were required to maintain concentrations in plasma within the effective range for most infections.
Single and multiple-dose pharmacokinetics of clinafloxacin have been reported previously (2, 17) . Following administration of 200-and 400-mg twice-daily intravenous doses, the mean total body clearance and volume of distribution values are approximately 320 ml/min and 156 liters, respectively, and the mean terminal elimination half-life (t 1/2 ) is approximately 5.8 h. Clinafloxacin is approximately 50% bound to plasma proteins, independent of concentration.
Approximately 50 to 70% of a clinafloxacin dose is excreted unchanged in urine, indicating that renal clearance (CL R ) is a primary route of drug elimination. Therefore, it is expected that clinafloxacin concentrations in patients having decreased renal function will be higher than those in patients having normal renal function when both sets of patients receive clinafloxacin at the same dose. Accordingly, single-dose clinafloxacin pharmacokinetic profiles were evaluated in subjects with various degrees of renal function to establish dosing recommendations for patients with decreased renal function. A major age-related physiological change that could potentially affect pharmacokinetic profiles is a change in excretion due to reduced glomerular filtration and diminished renal tubular function. Additional age-related changes that could affect pharmacokinetic profiles include changes in absorption due to reduced gastric acid production, lower gastric emptying rate, decreased motility, reduced blood flow, and reduced absorptive surface area; changes in distribution due to decreased total body mass, reduced proportion of body water, less plasma albumin and ␣ 1 -acid glycoprotein, increased proportion of body fat, and altered tissue perfusion; and changes in metabolism due to reduced liver mass, decreased liver blood flow, and reduced hepatic metabolic capacity. (11) Therefore, a study was also conducted to compare clinafloxacin pharmacokinetic profiles in young and elderly subjects to establish dosing recommendations in elderly subjects. In addition, a study was conducted in patients with severe renal impairment requiring hemodialysis to determine if additional clinafloxacin doses are required to maintain concentrations in plasma within the safe and effective range in these patients. [18, 19] .)
MATERIALS AND METHODS
Subjects and study conduct. Study protocols were approved by institutional review boards associated with the study sites, and all studies were conducted according to the ethical principles stated in the Declaration of Helsinki. All subjects provided written informed consent before entering the study and were free to withdraw at any time at their own discretion. Eligible subjects were men and women in good to excellent health according to degree of renal function and who had no unstable medical problems. Health was evaluated by medical history, physical examination, and clinical laboratory measurements. Subjects were confined to the clinic for 24 h following the administration of the clinafloxacin dose for safety evaluation by physicians and returned to the clinic for additional scheduled blood sampling.
Study 1: young and elderly subjects. Sixteen healthy subjects between 18 and 35 years old and 16 healthy elderly subjects (Ͼ65 years old) were enrolled in this study. Subject enrollment groups were equally divided by sex in order to evaluate any possible differences in clinafloxacin pharmacokinetic profiles between the sexes.
Study 2: subjects having mild, moderate, and severe renal impairment. To ensure enrollment of subjects having a wide range of renal function, 20 subjects were enrolled in one of three groups based on creatinine clearance (CL CR ) values estimated using the method of Cockcroft and Gault (4). Groups had CL CR values of Ͼ60 ml/min, between 30 and 60 ml/min, and Ͻ30 ml/min but not on dialysis. At least three subjects in the third group were to have a CL CR of Ͻ15 ml/min. Study 3: subjects having severe renal impairment requiring hemodialysis. Twelve subjects having renal impairment severe enough to require hemodialysis and maintained on hemodialysis at least once weekly were enrolled in this study. Subjects could be anuric (Ͻ 50 ml of urine per 24 h).
Design of studies.
All studies were open-label, single-dose, parallel-group designs. Subjects having various degrees of renal impairment, including those having severe renal impairment requiring hemodialysis, received single 200-mg clinafloxacin oral doses with 240 ml of water. Young and elderly subjects received single 400-mg clinafloxacin oral doses. Subjects maintained on hemodialysis received the dose approximately 24 h before their next scheduled hemodialysis treatment. Subjects not maintained on hemodialysis fasted overnight before and for 4 h following administration of the dose. Subjects requiring hemodialysis fasted for 4 h before and after the dose. Identical lunches and identical dinners were served to each subject after collection of the 4-and 10-h blood samples, respectively. Essential medication was allowed before and after the 8-h fasting period in these subjects in order to eliminate any potential drug interaction. It has been shown that oral clinafloxacin should be administered at least 2 h before or 4 h after administration of a magnesium-or aluminum-containing antacid and that clinafloxacin may be administered without regard to meals or meal timing (1) .
Safety. Subjects were required to remain in the clinic for 24 h following the administration of the dose for safety observation by physicians. Physical examinations including vital signs were conducted prior to the dose, at 4 and 24 h following the dose, and at closeout. Clinical laboratory tests were conducted prior to and at 24 h following the dose.
Sampling. For subjects not maintained on hemodialysis, venous blood samples (3 ml) were collected into heparinized tubes before the clinafloxacin dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 h postdose. For subjects maintained on hemodialysis, 2-ml samples were collected before the clinafloxacin dose and at 1, 2, 4, 8, and 12 h postdose. Blood samples were also collected from subjects entering and exiting the dialyzer before as well as 1, 2, 3, and 4 h after the beginning of hemodialysis (equivalent to 24, 25, 26, 27, and 28 h postdose). Additional blood samples were collected 1 and 2 h after the end of hemodialysis (equivalent to 29 and 30 h postdose) and at 32, 36, and 48 h postdose. Blood samples were immediately centrifuged, and plasma was separated and stored frozen in plastic containers at Ϫ20°C until assayed. For all subjects, a 100-ml urine specimen was collected before the dose. All urine voided during the 0-to 6-, 6-to 12-, 12-to 24-, 24-to 48-, 48-to 72-, and 72-to 96-h time intervals was collected. Total urine volumes were measured for each urine collection period, and 20-ml portions were stored frozen at Ϫ20°C until assayed. Dialysate samples (20 ml) were collected at the start of hemodialysis; at 1, 2, and 3 h after beginning hemodialysis; and upon completion of hemodialysis (equivalent to 24, 25, 26, 27, and 28 h postdose). Hemodialysate flow rate, blood inflow rate, dialyzer membrane surface area, and temperature were recorded. Dialysate samples were stored frozen at Ϫ20°C until assayed.
Assay of clinafloxacin. Plasma and urine samples were assayed for clinafloxacin concentration using validated liquid chromatographic methods with UV detection as described previously (17) . Dialysate samples were assayed by the urine method. Detector responses were linear over the calibration range of 0.025 to 10 g/ml and 2.5 to 200 g/ml for plasma and urine, respectively. Intra-and interday assay precision, as measured by the coefficient of variation, was Ͻ15% for both plasma and urine. No interfering peaks were evident in samples collected prior to clinafloxacin dosing, indicating that essential medications required by some subjects did not interfere with the clinafloxacin assay.
Pharmacokinetic analysis. For all subjects, maximum concentrations in plasma (C max ) and time to C max (T max ) were recorded as observed. The area under the concentration-time curves (AUC) values were estimated using the linear trapezoidal rule. AUC values were calculated from zero time to the time of the last quantifiable concentration (LQC). Values of terminal-phase elimination rate constants ( z ) were estimated as the absolute values of the slope of a least-squares regression line of natural logarithm (ln) concentration-time profiles during the terminal phase. The t 1/2 values were calculated as ln(2)/ z . In subjects not maintained on hemodialysis, values of AUC at infinity (AUC ϱ ) were calculated as the sum of corresponding values of AUC at the LQC and LQC/ z values. Total apparent body clearance of clinafloxacin from the plasma after oral administration (CL oral ) was calculated as dose/AUC ϱ . The apparent volume of distribution after oral administration (V oral ) was calculated as (CL oral )/ z . The total amount of drug excreted in urine during the 96-h postdose interval as unchanged clinafloxacin (Ae) was calculated as the product of urine volume and concentration. The percentage of the dose excreted (Ae%) as unchanged clinafloxacin was calculated as (Ae/dose) ⅐ 100. CL R was calculated as Ae/AUC ϱ . Because the absolute bioavailability of clinafloxacin from capsules in normal subjects is approximately 90% (17) , nonrenal clearance (CL NR ) values were approximated as the difference between CL oral and CL R . In subjects maintained on hemodialysis, AUC ϱ values were calculated as the sum of corresponding AUC 24 and C 24 / z values, where AUC 24 is the AUC at 24 h postdose and C 24 is the concentration in the sample collected 24 h postdose, immediately before the start of hemodialysis. These values represent pharmacokinetic parameters for subjects requiring hemodialysis who were not on hemodialysis at the time. Values for t 1/2 were estimated during as well as after hemodialysis. Hemodialysis clearance (CL d ) values were calculated as follows:
, where C in and C out are plasma clinafloxacin concentrations measured in blood samples entering and exiting the dialyzer, respectively, and, Qb and HCT are blood flow rate entering the dialyzer and hematocrit measured at each collection time, respectively (11). Individual time point CL d values obtained by this method were used to calculate an average subject CL d . The fraction of dose removed from the body by hemodialysis was calculated as Values for Ae% and CL R for anuric subjects were set at zero for evaluation of descriptive statistics. Clinafloxacin concentrations in dialysate were below the limit of quantitation (2.5 g/ml) in all samples for all subjects. Therefore, dialysate concentrations were not used in data analyses. Statistical methods. Mean clinafloxacin pharmacokinetic parameter values following administration of single 400-mg oral doses were compared between age groups and between sexes within age groups for possible clinically important differences. To assess which physiologic variable might best predict changes in key pharmacokinetic parameters, an analysis of covariance model consisting of CL CR , body weight, age (as a continuous variable), and sex as main effects was fitted using forward stepwise regression (SAS Institute, Cary, N.C.). Parameter estimates and coefficients of multiple determination were evaluated. The ability of each successive model to predict a given pharmacokinetic parameter was assessed by comparing variability with those of simpler models.
Graphical presentations of relationships between individual CL CR and pharmacokinetic parameter values were inspected for trends of possible clinical significance. Regression analysis was used to assess the relationships between subject CL CR values and CL oral and CL R values. All 32 subjects completing the young-elderly study and 19 subjects having various degrees of renal function were used in this regression evaluation. Outliers were determined using standard statistical procedures (8) . Mean clinafloxacin pharmacokinetic parameters for subjects who were maintained on hemodialysis were compared with those for subjects with severely impaired renal function but not maintained with hemodialysis for differences likely to be of clinical importance and to determine whether further dose adjustment is required in patients maintained on hemodialysis. Values for Ae% were examined to determine whether supplemental clinafloxacin doses are required to maintain effective plasma clinafloxacin concentrations in patients with renal impairment requiring hemodialysis.
RESULTS
Subject demographics and safety. Subject demographics are summarized in Table 1 and dialysis specifications are given in Table 2 . In general, single, 200-and 400-mg clinafloxacin oral doses were well tolerated by subjects with various degrees of renal impairment as well as healthy young and elderly subjects. In the young-elderly study, a 25-year-old male subject with a history of migraine headaches and a family history of childhood seizures in a sibling experienced a tonic-clonic seizure considered to be probably related to clinafloxacin, about 45 min following administration of the single 400-mg dose. The subject fully recovered within 30 min. The clinafloxacin pharmacokinetic profile in this subject was similar to that observed in other younger subjects in this study, and data from this subject were utilized in pharmacokinetic and statistical evalu- ations. No other serious adverse events were recorded in these studies. Clinical laboratory abnormalities were in general sporadic and transient and appeared to be unrelated to drug administration. Many quinolone anti-infective agents are reported to have central nervous system-related adverse events, including seizures (3, 9, 13).
Pharmacokinetics. (i) Elderly versus young subjects.
Mean clinafloxacin concentration-time profiles following administration of single 400-mg oral doses to young and elderly subjects are illustrated in Fig. 1 . Clinafloxacin pharmacokinetic parameter values are given in Table 3 . Parameter values determined for young healthy subjects were similar to those reported previously (17) . Clinafloxacin was rapidly absorbed in young and elderly subjects. Values for T max ranged from 0.5 to 3 h and were independent of subject age. The mean C max for elderly subjects was approximately 18% higher than that observed in younger subjects. This difference probably reflects differences in clearance. The mean AUC ϱ following administration of clinafloxacin capsules in elderly subjects was 57% higher than that observed in younger subjects. The mean t 1/2 in elderly subjects was 41% higher than that in younger subjects. Mean CL oral and CL R values in the elderly were 35 and 45% lower than those in younger subjects. As a result of these differences in CL oral and CL R values, plasma clinafloxacin concentrations were higher in elderly subjects than in young subjects. V oral and Ae% values in elderly subjects were similar to those in younger subjects, with differences in mean values being approximately 9% and 14%, respectively.
Clinafloxacin pharmacokinetic parameter values separated by sex are given in Table 4 . Plasma clinafloxacin concentrations, as reflected in C max and AUC ϱ values, tended to be slightly higher in female subjects than in male subjects, in both age groups. Differences in CL oral values between male and female subjects within age groups were small (Ͻ30% in each case). The difference in mean V oral values was modest, the values being 149 and 100 liters for male and female subjects, respectively.
Results from the forward selection analysis of covariance procedure suggested that CL CR , age, and sex were statistically significant predictors of clinafloxacin CL oral values. The principle predictor covariate, however, was CL CR , which when incorporated into the model reduced the variability in predicted versus observed apparent clearance values. Addition of age and sex to the model, while statistically significant, resulted in only a slight further reduction in variability. CL CR , age, and sex were statistically significant predictors of CL R values. Inclusion of only CL CR in the model, however, resulted in a meaningful reduction in observed variability. Addition of age and sex, while statistically significant, reduced variability only slightly. Sex was the most significant predictor of V oral values. The difference between a model consisting of sex alone and a model consisting of body weight alone was substantial. Age, CL CR , and body weight added little to the predictability.
In summary, differences in clinafloxacin CL oral and CL R between young and elderly subjects are largely accounted for by differences in CL CR due to age-related decline in renal function.
(ii) Subjects with various degrees of renal function not maintained on hemodialysis. Relationships between CL oral and CL R values with subject CL CR values are illustrated in Fig.  2 and 3 , respectively. Young and elderly subjects were included with those having various degrees of renal function. Both CL oral and CL R correlated with decreasing renal function with the following relationship: CL oral ϭ 2.3 ⅐ CL CR ϩ 77 and CL R ϭ 1.74 ⅐ CL CR . As expected for a drug eliminated primarily by renal excretion, CL oral correlated well with CL CR . Correlation coefficients were 0.88 and 0.93 relating CL oral and CL R to CL CR , respectively. A positive intercept in the relationship between CL oral and CL CR indicated the presence of a significant nonrenal clearance component, representing approximately 25 to 30% of CL oral . This was supported by the approximate CL NR values in young subjects having normal renal function given in Table 3 .
The excellent correlation observed between CL oral and subject CL CR values was used to predict CL oral values in subjects with various degrees of renal function according to previously published methods (14, 15, 20, 21) . Using these relationships, subjects having a CL CR between 30 and 40 ml/min would be expected to have approximately one-half of the clinafloxacin CL oral observed in subjects having normal renal function, i.e., a CL CR of 100 to 120 ml/min. Therefore, as a conservative measure, a CL CR of 40 ml/min was selected as the breakpoint below which the clinafloxacin dose should be reduced. Pharmacokinetic parameter values in subjects having CL CR values of Ͼ40 ml/min and those with CL CR values of Ͻ40 ml/min are summarized in Table 5 . These values include young and elderly (iii) Subjects maintained on hemodialysis. Mean clinafloxacin concentration-time profiles following administration of single 200-mg oral doses to subjects maintained on hemodialysis are shown in Fig. 4 . The figure also illustrates concentrations in plasma exiting the dialyzer. Pharmacokinetic parameter values for this group of subjects are summarized in Table 5 . Parameter values were similar to those in subjects with CL CR values of Ͻ40 ml/min who were not maintained on hemodialysis. Approximately 4% of a single 200-mg clinafloxacin dose was removed by the 4-h hemodialysis procedure.
DISCUSSION
Based on similar T max and C max values, rates of clinafloxacin absorption are similar in young and elderly male and female subjects. Small differences in C max values among these groups is of no clinical importance. Based on similar V oral values between age groups, distributions of clinafloxacin were similar in young and elderly male and female subjects. V oral values were greater than total body water, suggesting extensive distribution of clinafloxacin into tissues in all subjects. Based on similar CL NR values in young and elderly male and female subjects, clinafloxacin metabolism and/or other elimination mechanisms (that is, biliary excretion) are not influenced by age or sex differences. The major factor responsible for higher clinafloxacin concentrations in plasma in the elderly is an agerelated decrease in renal function. Therefore, reduction in daily clinafloxacin dose based on degree of renal function as measured by CL CR values may be appropriate for the elderly. Differences in pharmacokinetic parameter values between male and female subjects, regardless of age, are not clinically important and do not warrant clinafloxacin dose adjustment based on sex.
The recommended clinafloxacin dose in patients with normal renal function is 200 mg twice daily. Based on the relationship between clinafloxacin CL oral and subject CL CR values, it is recommended that patients with CL CR values of Ͻ40 ml/min, regardless of age, have their daily clinafloxacin dose halved. Therefore, these patients should receive either 100 mg of clinafloxacin twice daily or 200 mg once daily to maintain plasma clinafloxacin concentrations within the range effective for most organisms. This dosing regimen is also recommended for patients on hemodialysis. As only 4% of the clinafloxacin dose is removed by the 4-h hemodialysis procedure, supplemental clinafloxacin doses are not required during or after hemodialysis.
